{"id":"cetirizine-zyrtec","safety":{"commonSideEffects":[{"rate":"2-3%","effect":"Headache"},{"rate":"1-2%","effect":"Somnolence"},{"rate":"1-2%","effect":"Fatigue"},{"rate":"1-2%","effect":"Dry mouth"},{"rate":"1-2%","effect":"Pharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetirizine competitively inhibits histamine at H1 receptors, which are responsible for allergic responses including itching, sneezing, and urticaria. As a second-generation antihistamine, it is highly selective for H1 receptors and has minimal central nervous system penetration due to its hydrophilic nature and poor blood-brain barrier crossing, resulting in reduced sedation compared to first-generation antihistamines.","oneSentence":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on cells, preventing allergic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:21.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis (seasonal and perennial)"},{"name":"Chronic urticaria"},{"name":"Allergic conjunctivitis"},{"name":"Allergic dermatitis"}]},"trialDetails":[{"nctId":"NCT07478315","phase":"NA","title":"IMPOWER-QoL: IMPact Of Discontinuing Premedication for WEekly Paclitaxel on bReast Cancer Patient's Quality Of Life","status":"NOT_YET_RECRUITING","sponsor":"Charles LeMoyne Hospital","startDate":"2026-03-15","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT07472413","phase":"PHASE3","title":"Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-07-01","conditions":"Multiple Sclerosis","enrollment":60},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT07426822","phase":"PHASE2","title":"Rash & Diarrhea Prophylaxis With Capivasertib","status":"NOT_YET_RECRUITING","sponsor":"Maryam Lustberg","startDate":"2026-04","conditions":"Metastatic HR+/HER2- Breast Cancer","enrollment":108},{"nctId":"NCT05660083","phase":"PHASE2","title":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-12","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma","enrollment":36},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT02535416","phase":"PHASE1","title":"A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT06120673","phase":"PHASE3","title":"REmission in Membranous Nephropathy International Trial (REMIT)","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2025-10-31","conditions":"Primary Membranous Nephropathy","enrollment":""},{"nctId":"NCT07236372","phase":"NA","title":"Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria","status":"NOT_YET_RECRUITING","sponsor":"University of Phayao","startDate":"2025-11","conditions":"Acute Urticaria","enrollment":140},{"nctId":"NCT04568902","phase":"PHASE1","title":"Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-09-30","conditions":"Breast Neoplasms","enrollment":33},{"nctId":"NCT06019728","phase":"PHASE4","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-10","conditions":"Fabry's Disease","enrollment":8},{"nctId":"NCT05946551","phase":"PHASE3","title":"Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial","status":"TERMINATED","sponsor":"Emory University","startDate":"2024-03-08","conditions":"COVID-19","enrollment":5},{"nctId":"NCT06890260","phase":"NA","title":"The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife","status":"RECRUITING","sponsor":"Pengfei Qiu","startDate":"2025-04-11","conditions":"Allergic Rhinitis (Disorder), Electroacupuncture, Microneedle Knife","enrollment":90},{"nctId":"NCT06819774","phase":"PHASE3","title":"Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria","status":"RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2024-04-22","conditions":"Acute Urticaria","enrollment":284},{"nctId":"NCT06754410","phase":"PHASE3","title":"Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study","status":"COMPLETED","sponsor":"South Valley University","startDate":"2021-03-01","conditions":"Lower Ureteric Stones","enrollment":480},{"nctId":"NCT03167216","phase":"EARLY_PHASE1","title":"Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-08-01","conditions":"Chronic Prostatitis With Chronic Pelvic Pain Syndrome","enrollment":20},{"nctId":"NCT04323566","phase":"PHASE2","title":"Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement","status":"ENROLLING_BY_INVITATION","sponsor":"Uppsala University Hospital","startDate":"2022-05-01","conditions":"Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia","enrollment":40},{"nctId":"NCT06118710","phase":"PHASE4","title":"Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-06-25","conditions":"Cancer","enrollment":500},{"nctId":"NCT06039137","phase":"","title":"The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-06-01","conditions":"Solid Tumor","enrollment":395},{"nctId":"NCT00751218","phase":"PHASE4","title":"A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-05-06","conditions":"Urticaria","enrollment":174},{"nctId":"NCT00751166","phase":"PHASE4","title":"A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Urticaria","enrollment":149},{"nctId":"NCT06535087","phase":"","title":"The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","status":"RECRUITING","sponsor":"Wenjing Zhou","startDate":"2024-07-20","conditions":"Pediatric Asthma, Rhinitis, Allergic, Quality of Life","enrollment":600},{"nctId":"NCT04071821","phase":"PHASE1","title":"Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg","status":"NOT_YET_RECRUITING","sponsor":"Seattle Gummy Company","startDate":"2025-05-01","conditions":"Allergy","enrollment":30},{"nctId":"NCT00650065","phase":"PHASE1","title":"Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT00649857","phase":"PHASE1","title":"Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec® 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT04990388","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)","status":"TERMINATED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-10-18","conditions":"Glycogen Storage Disease Type III","enrollment":9},{"nctId":"NCT02024152","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg","status":"COMPLETED","sponsor":"JDP Therapeutics, Inc.","startDate":"2011-03","conditions":"Acute Urticaria","enrollment":24},{"nctId":"NCT05095311","phase":"PHASE4","title":"The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers","status":"TERMINATED","sponsor":"Indiana University","startDate":"2021-05-19","conditions":"Exercise-induced Arterial Hypoxemia","enrollment":16},{"nctId":"NCT04175834","phase":"PHASE3","title":"Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2020-02-05","conditions":"Multiple Sclerosis, Infusion Reaction","enrollment":19},{"nctId":"NCT06288334","phase":"PHASE4","title":"Exploration of the Optimal Dosage of Cetirizine in the Treatment of Allergic Diseases in Chinese Children","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2020-08-06","conditions":"Allergic Disease, Children","enrollment":80},{"nctId":"NCT02023164","phase":"PHASE3","title":"Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria","status":"COMPLETED","sponsor":"JDP Therapeutics, Inc.","startDate":"2013-07","conditions":"Acute Urticaria","enrollment":36},{"nctId":"NCT06126991","phase":"PHASE1, PHASE2","title":"Organ Protective Effect of Cetirizine In Patients With Severe Burns","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2024-01-23","conditions":"Burns","enrollment":32},{"nctId":"NCT05476679","phase":"PHASE1, PHASE2","title":"Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events","status":"COMPLETED","sponsor":"Raziel Therapeutics Ltd.","startDate":"2022-09-25","conditions":"Submental Fat","enrollment":48},{"nctId":"NCT05275933","phase":"PHASE2, PHASE3","title":"Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang in Mild COVID-19 Patients","status":"COMPLETED","sponsor":"Singapore Chung Hwa Medical Institution","startDate":"2022-04-05","conditions":"COVID-19","enrollment":93},{"nctId":"NCT04189588","phase":"PHASE2","title":"Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine","status":"COMPLETED","sponsor":"TerSera Therapeutics LLC","startDate":"2020-03-25","conditions":"Oncology Patients Receiving Chemotherapy","enrollment":34},{"nctId":"NCT05922358","phase":"PHASE2","title":"Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-09-01","conditions":"Gastrointestinal Tumors","enrollment":500},{"nctId":"NCT02865018","phase":"PHASE1, PHASE2","title":"Neuromyelitis Optica (NMO) & Cetirizine","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-04","conditions":"Neuromyelitis Optica","enrollment":16},{"nctId":"NCT05803070","phase":"","title":"Topical Cetirizine in Treatment of Localized Alopecia Areata","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-09-01","conditions":"Alopecia Areata","enrollment":59},{"nctId":"NCT04481412","phase":"PHASE2, PHASE3","title":"Topical Cetirizine in Androgenetic Alopecia in Females","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-07-25","conditions":"Androgenetic Alopecia","enrollment":66},{"nctId":"NCT05673746","phase":"NA","title":"Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2020-09-01","conditions":"Peripheral Neuropathy","enrollment":102},{"nctId":"NCT03340740","phase":"PHASE4","title":"The Effect of Cetirizine on Bronchoconstriction","status":"COMPLETED","sponsor":"New York City Health and Hospitals Corporation","startDate":"2018-05-11","conditions":"Allergic Rhinitis, Asthma","enrollment":40},{"nctId":"NCT00794846","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":124},{"nctId":"NCT00794599","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":118},{"nctId":"NCT00794495","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":122},{"nctId":"NCT00794794","phase":"PHASE3","title":"Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11","conditions":"Allergic Rhinitis","enrollment":204},{"nctId":"NCT00794378","phase":"PHASE3","title":"Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11","conditions":"Allergic Rhinitis","enrollment":202},{"nctId":"NCT00780403","phase":"PHASE4","title":"Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Allergies","enrollment":220},{"nctId":"NCT00779116","phase":"PHASE4","title":"Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Allergies","enrollment":217},{"nctId":"NCT00974571","phase":"PHASE3","title":"Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-11","conditions":"Perennial Allergic Rhinitis","enrollment":1365},{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT03772158","phase":"PHASE1","title":"Cetirizine Chewable Bioequivalence and Food Effect Study","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division","startDate":"2018-12-11","conditions":"Allergy","enrollment":40},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT04836806","phase":"PHASE4","title":"Cetirizine and Famotidine for COVID-19","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2021-08","conditions":"Covid19","enrollment":""},{"nctId":"NCT04935515","phase":"NA","title":"C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.","status":"COMPLETED","sponsor":"Manimarane Arjunan, MD,DM (Cardiology)","startDate":"2021-04-15","conditions":"COVID -19","enrollment":25},{"nctId":"NCT02583594","phase":"PHASE1","title":"A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-12-06","conditions":"Progressive Multiple Sclerosis","enrollment":24},{"nctId":"NCT04612803","phase":"","title":"Prevalence of Antihistamine Responsive Irritable Bowel Syndrome With Diarrhea","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2020-11-15","conditions":"Irritable Bowel Syndrome, Dermatographism, Post-prandial Diarrhea","enrollment":100},{"nctId":"NCT04237090","phase":"PHASE3","title":"Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2020-02-14","conditions":"Breast Cancer, Lung Cancer, Ovarian Cancer","enrollment":27},{"nctId":"NCT02394119","phase":"PHASE2","title":"Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome","status":"COMPLETED","sponsor":"Istituto Giannina Gaslini","startDate":"2015-06","conditions":"Nephrotic Syndrome","enrollment":140},{"nctId":"NCT02394106","phase":"PHASE2","title":"Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome","status":"TERMINATED","sponsor":"Istituto Giannina Gaslini","startDate":"2015-07","conditions":"Nephrotic Syndrome","enrollment":13},{"nctId":"NCT03192488","phase":"PHASE4","title":"Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia","status":"COMPLETED","sponsor":"Indiana University","startDate":"2017-08-31","conditions":"Hypoxia, Altitude","enrollment":13},{"nctId":"NCT04293822","phase":"PHASE4","title":"Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-06","conditions":"Androgenetic Alopecia","enrollment":60},{"nctId":"NCT02665754","phase":"PHASE1","title":"Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2016-07","conditions":"Allergic Rhinitis","enrollment":32},{"nctId":"NCT03296358","phase":"NA","title":"Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2017-10-01","conditions":"Urticaria, Allergy","enrollment":75},{"nctId":"NCT02935699","phase":"PHASE3","title":"Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria","status":"COMPLETED","sponsor":"JDP Therapeutics, Inc.","startDate":"2017-03-01","conditions":"Acute Urticaria","enrollment":262},{"nctId":"NCT03047278","phase":"PHASE4","title":"Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain.","status":"COMPLETED","sponsor":"Natalia Valadares de Moraes","startDate":"2015-11-01","conditions":"Neuropathic Pain, Type 2 Diabetes Mellitus, Diabetic Neuropathy, Painful","enrollment":29},{"nctId":"NCT01241214","phase":"PHASE2","title":"Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2010-11","conditions":"Seasonal Allergic Rhinitis","enrollment":579},{"nctId":"NCT02543346","phase":"PHASE4","title":"Comparability and Standardization of Controlled Allergen Challenge Facilities","status":"COMPLETED","sponsor":"Queen's University","startDate":"2015-10","conditions":"Allergic Rhinitis","enrollment":98},{"nctId":"NCT01825655","phase":"PHASE4","title":"Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2014-09","conditions":"Pruritus","enrollment":3},{"nctId":"NCT01484119","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2011-12","conditions":"Seasonal Allergic Rhinitis","enrollment":630},{"nctId":"NCT00291642","phase":"PHASE2","title":"A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-01-01","conditions":"Rhinitis, Allergic, Seasonal","enrollment":551},{"nctId":"NCT01916226","phase":"PHASE4","title":"A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08-01","conditions":"Rhinitis, Allergic, Perennial and Seasonal","enrollment":682},{"nctId":"NCT01651871","phase":"PHASE2","title":"Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Shionogi","startDate":"2012-07","conditions":"Seasonal Allergic Rhinitis","enrollment":779},{"nctId":"NCT01451996","phase":"PHASE4","title":"The Efficacy of Claritin in Healthy Subjects","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-10","conditions":"Healthy","enrollment":340},{"nctId":"NCT01881113","phase":"PHASE3","title":"A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2013-06","conditions":"Allergic Conjunctivitis","enrollment":101},{"nctId":"NCT01551056","phase":"PHASE3","title":"A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2012-03","conditions":"Allergic Conjunctivitis","enrollment":91},{"nctId":"NCT01685242","phase":"PHASE3","title":"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2012-09","conditions":"Allergic Conjunctivitis","enrollment":100},{"nctId":"NCT02173249","phase":"PHASE1","title":"A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2014-06","conditions":"Healthy","enrollment":11},{"nctId":"NCT01134328","phase":"PHASE2","title":"Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2010-05","conditions":"Allergic Conjunctivitis","enrollment":83},{"nctId":"NCT01495338","phase":"PHASE1","title":"A Comparison of the Safety and Comfort of AC-170","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-12","conditions":"Normal Ocular Health","enrollment":60},{"nctId":"NCT02756624","phase":"PHASE3","title":"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2016-04","conditions":"Healthy Subjects","enrollment":516},{"nctId":"NCT02132169","phase":"PHASE3","title":"A Multi-Center Study Evaluating the Safety of AC-170 0.24%","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2014-05","conditions":"Atopic Disease (Including Allergic Conjunctivitis)","enrollment":512},{"nctId":"NCT01332188","phase":"PHASE2, PHASE3","title":"Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-04","conditions":"Allergic Conjunctivitis","enrollment":101},{"nctId":"NCT00490204","phase":"PHASE3","title":"Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-27","conditions":"Rhinitis, Allergic, Perennial","enrollment":239},{"nctId":"NCT02447393","phase":"PHASE1","title":"Phase 1 Study of Levocetirizine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-18","conditions":"Dermatitis","enrollment":20},{"nctId":"NCT00972504","phase":"PHASE2","title":"723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-01","conditions":"Rhinitis, Allergic, Seasonal","enrollment":54},{"nctId":"NCT00866788","phase":"PHASE2","title":"A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-03","conditions":"Chronic Idiopathic Urticaria","enrollment":90},{"nctId":"NCT02613910","phase":"PHASE3","title":"Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2015-12-23","conditions":"Pemphigus","enrollment":1},{"nctId":"NCT01622283","phase":"PHASE1","title":"Pharmacokinetic Study of Levocetirizine Oral Solution","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-02","conditions":"Rhinitis, Allergic, Perennial and Seasonal","enrollment":20},{"nctId":"NCT02932774","phase":"PHASE4","title":"Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2001-03","conditions":"Allergic Rhinitis, Hay Fever, SAR","enrollment":683},{"nctId":"NCT00881127","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-07","conditions":"Allergies","enrollment":40},{"nctId":"NCT00881634","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-06","conditions":"Allergies","enrollment":40},{"nctId":"NCT02451579","phase":"NA","title":"A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy","status":"COMPLETED","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2015-02","conditions":"Actinic Keratoses","enrollment":20},{"nctId":"NCT01103050","phase":"PHASE2","title":"A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03-22","conditions":"Allergic Rhinitis","enrollment":60},{"nctId":"NCT00851344","phase":"PHASE2","title":"Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09","conditions":"Rhinitis, Allergic, Seasonal","enrollment":54},{"nctId":"NCT02873364","phase":"PHASE3","title":"High Dose Vitamin D Supplementation in Chronic Spontaneous Urticaria","status":"UNKNOWN","sponsor":"Shiraz University of Medical Sciences","startDate":"2016-08","conditions":"Urticaria","enrollment":80},{"nctId":"NCT02205489","phase":"PHASE4","title":"Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":58},{"nctId":"NCT01985789","phase":"PHASE4","title":"Anti-histamines and Methacholine Challenges.","status":"COMPLETED","sponsor":"Don Cockcroft","startDate":"2013-11","conditions":"Asthma","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"DYSPNOEA"},{"count":4,"reaction":"FATIGUE"},{"count":4,"reaction":"NAUSEA"},{"count":4,"reaction":"TACHYCARDIA"},{"count":4,"reaction":"VOMITING"},{"count":2,"reaction":"ABDOMINAL PAIN"},{"count":2,"reaction":"ASTHENIA"},{"count":2,"reaction":"CHEST DISCOMFORT"},{"count":2,"reaction":"CONSTIPATION"},{"count":2,"reaction":"COUGH"}],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zyrtec®","Zyrtec"],"phase":"marketed","status":"active","brandName":"Cetirizine (Zyrtec)","genericName":"Cetirizine (Zyrtec)","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on cells, preventing allergic symptoms. Used for Allergic rhinitis (seasonal and perennial), Chronic urticaria, Allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}